Innovative drugs and treatments focused on the development and commercialization of oncology therapeutics.
Our pioneering drug compounds were developed at Wake Forest University and the University of Texas at Austin
The CBM drug portfolio focuses on the treatment of three cancers, acute myeloid leukemia
(AML), acute lymphoblastic leukemia (ALL) and pancreatic cancer. Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Combined, CBM’s platform offers a robust drug pipeline focused on the development and commercialization of drugs to treat unmet medical needs in oncology.
The CBM Drug Portfolio
The CBM drug portfolio contains patented technology focused on the treatment acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer. Developed at Wake Forest School of Medicine, CBM’s AML and ALL drug (“KPC34”) is a proprietary next generation drug that combines a DNA damaging agent with a targeted therapy designed to overcome multiple resistance mechanisms observed with gemcitabine, the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug. The competitive benefits of KPC34 include oral application for patients that cannot tolerate repeated cycles of chemotherapy, doubling the mean survival time verse some of the current standard of care treatments and studies further show high activity levels against human AML cells.
The second drug on the CBM platform was developed at University of Texas at Austin. The new drug, “DHA-dFdC”, has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity tests.